Biotechnology - Neurological, Markets & Marketing


Popular Filters

New entrants to multiple sclerosis market will drive 10% pa growth through 2018


The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Biogen Idec sees EU launch delay for Tecfidera on patent issues


In a filing with the Securities and Exchange Commission, US biotech firm Biogen Idec (Nasdaq: BIIB) said…

Biogen IdecBiotechnologyEuropeMarkets & MarketingNeurologicalPatentsRegulationTecfidera

Appeals Court rules against EMD Serono over Rebif deal with Pfizer


Germany's Merck KGaA (MRK: DE) says that a Pennsylvania appeals court has ruled against Merck in deciding…

BiotechnologyEMD SeronoLegalMarkets & MarketingMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebif

Growing US uptake of Genzyme's Aubagio at three months post-launch


Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary…

AubagioBiotechnologyGenzymeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSanofi

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio


French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches


The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

Novartis' Gilenya MS patient share growth in Europe likely driven by improved product satisfaction and efficacy-related


Swiss drug major Novartis' (NOVN: VX) Gilenya (fingolimod) has captured 5.4% of those multiple sclerosis…

AubagioBG-12Biogen IdecBiotechnologyEuropeGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalSanofi

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch


The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) Tysabri (natalizumab).…

AubagioBiogen IdecBiotechnologyElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalSanofiTysabri

European neurologists view Rxing of Biogen Idec's BG-12, Sanofi's Aubagio and Sanofi/Bayer's Lemtrada


More than 85% of surveyed neurologists in the European Union-5 (France, Germany, Italy, Spain and the…

AubagioBayerBG-12Biogen IdecBiotechnologyEuropeLemtradaMarkets & MarketingNeurologicalPharmaceuticalSanofi

Reimbursement outlook for DMT Alzheimer's therapies in Europe


Emerging potentially disease-modifying therapies (DMTs) for Alzheimer's disease will likely be reimbursed…

BiotechnologyEuropeMarkets & MarketingNeurologicalPharmaceuticalPricing

Drug shortages spur developments in neurometabolic treatments


A prolonged gap in the neurology market following the shutdown of a Genzyme production facility is tempting…

BiotechnologyMarkets & MarketingNeurologicalPharmaceuticalRare diseasesResearch

As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst


Following the September 2010 US launch, Swiss drug major Novartis’ (NOVN: VX) first-in-class, once-daily…

AubagioBiogen IdecBiotechnologyGilenyalaquinimodLemtradaMarkets & MarketingNeurologicalNovartisocrelizumabPharmaceuticalResearchRocheSanofiTeva Pharmaceutical Industries

Back to top